Kenneth Berlin compensation by year
Ayala Pharmaceuticals Summary Compensation Table · all 2 fiscal years held| Component | FY2021 | FY2022 |
|---|---|---|
| Salary | $569,670 | $643,427 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $0 | $0 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $55,728 | $60,341 |
| Total | $625,398 | $703,768 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ayala Pharmaceuticals, Inc. DEF 14A filed June 23, 2023, accession 0001493152-23-022199, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Ayala Pharmaceuticals, Inc. filed document, accession 0001493152-23-022199. Every figure is read from that document and cited to the page and table it appears in. Filed June 23, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 208 | — | $52.80 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Ayala Pharmaceuticals, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Ayala Pharmaceuticals discloses, by trigger · FY2022| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $870,144 | $0 | $26,038 | $1,279,045 |
| Change in control and involuntary termination | $2,157,996 | $0 | $41,660 | $2,582,519 |
| Death | $0 | $0 | $0 | $382,863 |
| Disability | $870,144 | $0 | $26,038 | $1,279,045 |
| Involuntary for cause | $0 | $0 | $0 | $0 |
| Voluntary resignation | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in Ayala Pharmaceuticals, Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.
Ayala Pharmaceuticals’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Kenneth Berlin · this page | President, Chief Executive Officer | $703,768 |
| Andres Gutierrez | Senior VP, Chief Medical Officer | $533,627 |
| Igor Gitelman | Interim Chief Financial Officer | $342,209 |
Board service
Ayala Pharmaceuticals board · FY2022How this board is paid
Company policy: Ayala Pharmaceuticals pays directors a $50,000 cash retainer. As stated in Ayala Pharmaceuticals's FY2022 proxy.
The full Ayala Pharmaceuticals compensation record
free company briefThis page is one person within Ayala Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ayala Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.